|Bid||101.33 x 1000|
|Ask||101.39 x 1000|
|Day's Range||100.63 - 107.10|
|52 Week Range||54.00 - 220.20|
|Beta (5Y Monthly)||2.24|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Nkarta Inc (NASDAQ: NKTX) has collaborated with CRISPR Therapeutics AG(NASDAQ: CRSP) to co-develop and commercialize two CAR-NK therapies, in addition to an NK+T program. The companies will split all the R&D costs and any worldwide profits, 50/50. CRISPR and Nkarta will start with a CAR-NK candidate targeting CD70 primarily for oncology indications. The target for their second CAR-NK program has yet to be revealed. In addition to those programs, Nkarta can license CRISPR’s technology to edit five gene targets in an unlimited number of its own NK cell therapies. For each non-collaboration candidate including a gene-editing target licensed from CRISPR, Nkarta will owe the company milestones and royalties on net sales. The agreement includes a three-year exclusivity period between the companies. Price Action: NKTX shares gained 8.96% at $20.18, while CRSP shares are up 2.62% at $110.67 on the last check Friday. See more from BenzingaClick here for options trades from BenzingaCronos Q1 Earnings Impacted By COVID-19 Related RestrictionsAnalysts React To FDA AdCom Vote On ChemoCentryx's Avacopan, Stock Plunges© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Long before they won the 2020 Nobel Prize in Chemistry for discovering the molecular gene-editing tool known as clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9, Jennifer Doudna and Emmanuelle Charpentier dreamed of Victoria Gray, a woman with sickle cell disease. Although they didn't know her, they knew that one day, a patient with a genetic disease would be cured using their discovery. Sickle cell disease was the logical place to start since it's the most common blood disorder with a single-gene mutation.
Vertex Pharmaceuticals (NASDAQ: VRTX) is the leader in cystic fibrosis (CF) treatment -- and it expects to hold that title until at least the late 2030s. The biotech company may be about to prove that, yes, it can. Vertex CEO Reshma Kewalramani made a statement about one of the company's most innovative, exciting programs during the recent earnings call.